Page 2500 - Williams Hematology ( PDFDrive )

2471
2470 Index Index 2471

acute, 999–1000 motility disorders, 1019t, 1026 nucleotides, 935, 935t
chronic, 1000 drugs and extrinsic agents and, 1026 opsonic receptors, 934t
classification, 984t familial Mediterranean fever, phenotypic changes, 934–935
clinical approach to, 1001 1024–1026 recruitment of, in inflammation, 283
consultative approach to, 44 hyperimmunoglobulin E syndrome, reference ranges, 18t, 19f
definition, 997, 999 1020t, 1026–1027, 1182, 1215t, release, 71, 71f
disorders associated with, 1000–1001 1225 structure, 925–926
etiology, 985–986, 999–1000, 1000t neutropenia. See Neutropenia band, 20f, 925–926, 926f, 927f, 939, 941t
mechanisms, 999–1000, 999f neutrophilia. See Neutrophilia inclusions, 23
pseudo-, 999–1000 qualitative abnormalities, 984t, 986 lipids, 935, 935t
in sickle cell disease, 765 signal mechanism abnormalities, 1017 mature, 925–926, 926f, 927f, 929f
vascular or tissue damage and, 984t, 986 vascular or tissue damage and, 984t, 986 metamyelocyte, 925–926, 926f, 927f,
Neutrophilic chronic myelogenous leukemia, evaluation of reserves, 943 929f
1449 function, 1005–1017 myeloblast, 925, 926f, 927f
Neutrophilic dermatosis (Sweet syndrome), adhesion, 1006 neutrophilic myelocyte, 925, 927f
1001, 1324, 1380, 2102–2103, 2102f adhesion and spreading, 1006–1008, promyelocyte, 925, 926f, 927f, 928f
Neutrophilic leukocytosis, 997. See also 1007f segmented, 20f
Neutrophilia carbohydrate metabolism, 932 Neutrophil serine protease 4 (NSP4), 1012t
Neutrophilic myelocyte, 925, 926f chemotaxis and motility, 1005 Neutrophil turnover rate (NTR), 941, 942,
Neutrophils, 22 ingestion, 1005–1006, 1006f 942t
abnormalities microvilli dynamics, 1006 Newborns/infants
in megaloblastic anemia, 594f, 595 protein synthesis, 932, 933t alloimmune hemolytic disease of. See
in myelodysplastic syndromes, 1350f, receptor-ligand interactions, Alloimmune hemolytic disease of
1353 1014–1017, 1015f the fetus and newborn (HDFN)
adhesion molecules, 934t rolling and tethering, 1006 alloimmune neutropenia in, 995, 2358
amino acids, 935, 935t secretory vesicles, 1009 alloimmune thrombocytopenia in,
apoptosis in, 285 stimulus-response coupling, 1014 2012–2013, 2359, 2361, 2362
biochemical features, 935, 935t surface proteins, 1008–1009 disseminated intravascular coagulation in,
chemotactic receptors, 934t transendothelial migration, 1008 2211
cytochemical reactions, 1049t granules, 1009–1011 hematology, 102–112. See also specific cell
definition and history, 939 abnormal, 23 type
disorders, 983–986, 1017–1034 azurophil. See Azurophil granules bone marrow, 32t
actin dysfunction, 1024 biosynthetic timing, 1010, 1010f coagulation, 109–111, 110t, 111t
adhesion abnormalities, 1019t, constitutive and regulated exocytotic erythropoiesis and red cells, 102–105,
1021–1024, 1021t, 1023f pathway, 1010–1011 103t, 104f, 105t
classification, 983, 984t, 1017 contents, 927, 930t lymphopoiesis, 108–109, 108t, 109t
clinical manifestations, 983–985 control of protein expression, 1010f, maternal drugs and, 112, 112t
degranulation abnormalities 1011 thrombopoiesis and platelets, 107–108
Chédiak-Higashi syndrome. See heterogeneity, 1009–1010 white cells, 105–107
Chédiak-Higashi syndrome microRNAs and, 1011 hemochromatosis, 640
specific granule deficiency, 1019t, nomenclature, 1009 hereditary elliptocytosis in, 679
1020–1021 peroxidase-negative, 1013–1014 hereditary pyropoikilocytosis in, 679
diagnostic approach, 1034, 1035f physical-chemical and functional hereditary spherocytosis in, 674
microbicidal activity defects properties of, 1011–1014, icterus in, 689, 707, 709
chronic granulomatous disease. See 1012–1013t immunoglobulin in, 2347
Chronic granulomatous disease structure, 926–927 iron deficiency in, 630, 632
glucose-6-phosphate dehydrogenase granulopoiesis, 939 jaundice in, 707, 709
(G6PD) deficiency. See Glucose-6- blood kinetics, 941–942, 942t leukemia in, 1379, 1386, 1515
phosphate dehydrogenase (G6PD) humoral regulators, 939–940 methemoglobinemia susceptibility in, 790
deficiency hyperplastic, 983 myeloproliferative syndromes in,
glutathione reductase and glutathione marrow kinetics, 940–941, 941t 1385–1386
synthetase deficiencies, 698, 700t, maturation of precursor cells, 940, 941f neutropenia in, 994, 995
701t, 705, 709, 1020t, 1033 migration into tissues, 942–943 neutrophil motility in, 1026
myeloperoxidase deficiency, 1020t, in inflammation, 289 polycythemia in, 879, 881
1033 life span, 943 red cell transfusion in, 2371, 2372t
Rac-2 deficiency, 1020t marrow, 32t thrombocytopenia in, 2011

Kaushansky_index_p2393-2506.indd 2471 9/21/15 3:22 PM